African Americans are less likely to receive curative treatment for hepatocellular carcinoma

Table 2 Multivariate logistic regressions comparing outcomes of hepatocellular carcinoma by race

Outcome	Race	Adjusted odds ratio	95%CI
Metastatic Hepatocellular Carcinoma1	African-American	Reference
	Caucasian	0.82	0.71-0.94
	Hispanic	0.87	0.73-1.05
	Other/unknown	0.84	0.70-1.001
Liver Decompensation2	African-American	Reference
	Caucasian	1.16	1.03-1.30
	Hispanic	1.28	1.10-1.51
	Other/unknown	1.14	0.995-1.31
Inpatient Mortality3	African-American	Reference
	Caucasian	0.78	0.65-0.93
	Hispanic	0.82	0.66-1.03
	Other/unknown	0.86	0.69-1.07

¹Model is adjusted for age, sex, race, geographic region, hepatitis C, alcohol, non-alcoholic steatohepatitis (NASH), liver decompensation features, and Elixhauser comorbidity score;

²Model is adjusted for age, sex, race, geographic region, hepatitis C, alcohol, NASH, primary biliary cirrhosis, metastasis, and Elixhauser comorbidity score;

³Model is adjusted for age, sex, race, geographic region hepatitis C, hepatitis B, alcohol, NASH, liver decompensation features, metastasis, and treatment.